BWX Technologies, Inc. $BWXT Shares Bought by Meitav Investment House Ltd.

Meitav Investment House Ltd. raised its stake in BWX Technologies, Inc. (NYSE:BWXT) by 480.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,205 shares of the technology company’s stock after purchasing an additional 19,205 shares during the quarter. Meitav Investment House Ltd.’s holdings in BWX Technologies were worth $4,745,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Aventura Private Wealth LLC purchased a new stake in shares of BWX Technologies during the fourth quarter worth approximately $29,000. WFA of San Diego LLC purchased a new position in BWX Technologies in the 2nd quarter valued at $29,000. Strategic Advocates LLC purchased a new position in BWX Technologies in the 3rd quarter valued at $32,000. MV Capital Management Inc. acquired a new position in BWX Technologies in the 4th quarter valued at $32,000. Finally, Tucker Asset Management LLC acquired a new position in BWX Technologies in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 94.39% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BWXT. Deutsche Bank Aktiengesellschaft upgraded shares of BWX Technologies from a “hold” rating to a “buy” rating and upped their price objective for the stock from $205.00 to $255.00 in a research report on Friday, May 15th. TD Cowen started coverage on shares of BWX Technologies in a research note on Thursday, March 12th. They set a “buy” rating and a $230.00 price target on the stock. Zacks Research cut shares of BWX Technologies from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Truist Financial raised their price objective on shares of BWX Technologies from $205.00 to $212.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of BWX Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $228.00.

BWX Technologies Price Performance

NYSE:BWXT traded down $8.93 during trading hours on Tuesday, hitting $187.97. The company’s stock had a trading volume of 156,704 shares, compared to its average volume of 1,025,945. The business’s 50-day moving average is $200.87 and its two-hundred day moving average is $202.69. The company has a market capitalization of $17.22 billion, a PE ratio of 50.32, a PEG ratio of 3.22 and a beta of 0.74. The company has a debt-to-equity ratio of 1.58, a quick ratio of 2.33 and a current ratio of 2.40. BWX Technologies, Inc. has a 52-week low of $133.84 and a 52-week high of $241.82.

BWX Technologies (NYSE:BWXT) last released its earnings results on Monday, May 4th. The technology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $860.22 million during the quarter, compared to the consensus estimate of $837.47 million. BWX Technologies had a return on equity of 31.33% and a net margin of 10.20%.BWX Technologies’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.91 earnings per share. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. As a group, research analysts anticipate that BWX Technologies, Inc. will post 4.6 EPS for the current fiscal year.

BWX Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 5th. Investors of record on Tuesday, May 19th were paid a $0.27 dividend. The ex-dividend date was Tuesday, May 19th. This represents a $1.08 annualized dividend and a dividend yield of 0.6%. BWX Technologies’s dividend payout ratio (DPR) is 28.88%.

Insider Activity

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $204.81, for a total transaction of $2,048,100.00. Following the transaction, the chief executive officer directly owned 202,491 shares in the company, valued at approximately $41,472,181.71. This represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Thomas Fitzgerald sold 2,417 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $209.25, for a total transaction of $505,757.25. Following the completion of the transaction, the chief financial officer directly owned 6,884 shares of the company’s stock, valued at approximately $1,440,477. This trade represents a 25.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by company insiders.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.